TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Kupryjanczyk, Jolanta ^a,c   Kraszewska, Ewa ^b   Ziolkowska Seta, Izabela ^a   Madry, Radoslaw ^d   Timorek, Agnieszka ^c   Markowska, Janina ^d   Stelmachow, Jerzy ^c   Bidzinski, Mariusz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CLEAR CELL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41149129450     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-27     Document Type: Article

References (56)

1. McGuire WP Hoskins WJ Brady MF Kucera PR Partridge EE Look KY Clarke-Pearson DL Davidson M Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563
2. Trimble EL Wright J Christian MC Treatment of platinum-resistant ovarian cancer Expert Opin Pharmacother 2001, 2:1299-1306. 10.1517/ 14656566.2.8.1299 11584998
3. Stuart GC First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer Gynecol Oncol 2003, (Suppl 90):S8-15. 10.1016/S0090-8258(03)00472-4
4. Brown R Cellular responses to DNA damage and cisplatin resistance Ovarian Cancer 4 London: Chapmann and Hall Medical Sharp F, Blackett T, Leake R, Berek J 1996 Chapter 22 205-213
5. Sherman SE Lippard SJ Structural aspects of platinum anticancer drug interactions with DNA Chem Rev 1987, 87:1153-1181. 10.1021/cr00081a013
6. Jones NA Turner J McIlwrath AJ Brown R Dive C Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53 Mol Pharmacol 1998, 53:819-826. 9584207
7. Lowe SW Ruley HE Jacks T Housman DE p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993, 74:957-967. 10.1016/ 0092-8674(93)90719-7 8402885
8. Schiff PB Fant J Horwitz SB Promotion of microtubule assembly in vitro by taxol Nature 1979, 277:665-667. 10.1038/277665a0 423966
9. Dumontet C Sikic BI Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death J Clin Oncol 1999, 17:1061-1070. 10071301
10. Schiff PB Horwitz SB Taxol stabilizes microtubules in mouse fibroblast cells Proc Natl Acad Sci USA 1980, 77:1561-1565. 348536 6103535 10.1073/ pnas.77.3.1561
11. Rao S Orr GA Chaudhary AG Kingston DG Horwitz SB Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl) taxol photolabels a peptide (amino acids 217-231) of beta-tubulin J Biol Chem 1995, 270:20235-20238. 10.1074/jbc.270.34.20011 7657589
12. Wahl AF Donaldson KL Fairchild C Lee FY Foster SA Demers GW Galloway DA Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat Med 1996, 2:72-79. 10.1038/nm0196-72 8564846
13. Debernardis D Sire EG De Feudis P Vikhanskaya F Valenti M Russo P Parodi S D'Incalci M Broggini M P53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel Cancer Res 1997, 57:870-874. 9041188
14. Bellamy CO p53 and apoptosis Br Med Bull 1997, 53:522-38. 9374035
15. Righetti SC Della Torre G Pilotti S Menard S Ottone F Colnaghi MI Pierotti MA Lavarino C Cornarotti M Oriana S Bohm S Bresciani GL Spatti G Zunino F A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res 1996, 56:689-93. 8630996
16. Buttitta F Marchetti A Gadducci A Pellegrini S Morganti M Carnicelli V Cosio S Gagetti O Genazzani AR Bevilacqua G p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br J Cancer 1997, 75:230-5. 9010031
17. Ferrandina G Fagotti A Salerno MG Natali PG Mottolese M Maneschi F De Pasqua A Benedetti-Panici P Mancuso S Scambia G p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer Br J Cancer 1999, 81:733-40. 10.1038/sj.bjc.6690756 10574264
18. Baekelandt M Kristensen GB Nesland JM Trope CG Holm R Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer J Clin Oncol 1999, 17:2061. 10561259
19. Reles A Wen WH Schmider A Gee C Runnebaum IB Kilian U Jones LA El-Naggar A Minguillon C Schonborn I Reich O Kreienberg R Lichtenegger W Press MF Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 2001, 7:2984-97. 11595686
20. Kupryjanczyk J Szymanska T Madry R Timorek A Stelmachow J Karpinska G Rembiszewska A Ziolkowska I Kraszewska E Debniak J Emerich J Ulanska M Pluzanska A Jedryka M Goluda M Chudecka-Glaz A Rzepka-Gorska I Klimek M Urbanski K Breborowicz J Zielinski J Markowska J Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen Br J Cancer 2003, 88:848-854. 10.1038/sj.bjc.6600789 12644821
21. Smith-Sorensen B Kaern J Holm R Dorum A Trope C Borresen-Dale AL Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status Br J Cancer 1998, 78:375-381. 9703286
22. Lavarino C Pilotti S Oggionni M Gatti L Perego P Bresciani G Pierotti MA Scambia G Ferrandina G Fagotti A Mangioni C Lucchini V Vecchione F Bolis G Scarfone G Zunino F p53 gene status and response to platinum/ paclitaxel-based chemotherapy in advanced ovarian carcinoma J Clin Oncol 2000, 18:3936-3945. 11099323
23. Cassinelli G Supino R Perego P Polizzi D Lanzi C Pratesi G Zunino F A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes Int J Cancer 2001, 92:738-747. 10.1002/ 1097-0215(20010601)92:5<738::AID-IJC1249"3.0.CO;2-2 11340581
24. Ueno Y Enomoto T Otsuki Y Sugita N Nakashima R Yoshino K Kuragaki C Ueda Y Aki T Ikegami H Yamazaki M Ito K Nagamatsu M Nishizaki T Asada M Kameda T Wakimoto A Mizutani T Yamada T Murata Y Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin Cancer Lett 2006, 241:289-300. 10.1016/j.canlet.2005.10.035 16459017
25. Rakovitch E Mellado W Hall EJ Pandita TK Sawant S Geard CR Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/ M accumulation Int J Radiat Oncol Biol Phys 1999, 44:1119-24. 10421546
26. Gadducci A Di Cristofano C Zavaglia M Giusti L Menicagli M Cosio S Naccarato AG Genazzani AR Bevilacqua G Cavazzana AO P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome Anticancer Res 2006, 26:687-93. 16739339
27. Kupryjanczyk J Thor AD Beauchamp R Merritt V Edgerton SM Bell DA Yandell DW p53 gene mutations and protein accumulation in human ovarian cancer Proc Natl Acad Sci USA 1993, 90:4961-4965. 46633 8506342 10.1073/ pnas.90.11.4961
28. Dansonka-Mieszkowska A Ludwig AH Kraszewska E Kupryjanczyk J Geographical variations in TP53 mutational spectrum in ovarian carcinomas Ann Hum Gene t 2006, 70:594-604. 10.1111/ j.1469-1809.2006.00257.x
29. Van Dyke T Cancer biology: Sense out of missense Nature 2005, 434:287-8. 10.1038/434287a 15772635
30. Sigal A Rotter V Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome Cancer Res 2000, 60:6788-93. 11156366
31. Kupryjanczyk J Madry R Plisiecka-Halasa J Bar J Kraszewska E Ziolkowska I Timorek A Stelmachow J Emerich J Jedryka M Pluzanska A Rzepka-Gorska I Urbanski K Zielinski J Markowska J TP53 status determines clinical significance of ERBB2 expression in ovarian cancer Br J Cancer 2004, 91:1916-1923. 10.1038/sj.bjc.6602238 15545967
32. Kupryjanczyk J Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypotheses Gynecol Oncol 2006, 100:5-7. 10.1016/j.ygyno.2005.08.003 16169062
33. Tavassoli FA Devilee P Edited Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Health Organization Classification of Tumours, IARC Press Lyon 2003
34. Creasman WJ Announcement, FIGO stages revisions Gynecol Oncol 1988, 35:125-127.
35. Partridge EE Phillips JL Menck HR The National Cancer Data Base report on ovarian cancer treatment in United States hospitals Cancer 1996, 78:2236-46. 10.1002/ (SICI)1097-0142(19961115)78:10<2236::AID-CNCR28>3.0.CO;2-Z 8918420
36. Miller AB Hogestraeten B Staquet M Winkler A Reporting results of cancer treatment Cancer 1981, 47:207-214 10.1002/ 1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 7459811
37. Christian MC Trimble EL Salvage chemotherapy for epithelial ovarian carcinoma Gynecol Oncol 1994, (Suppl 55):S143-150. 10.1006/gyno.1994.1354
38. Kupryjanczyk J Bell DA Dimeo D Beauchamp R Thor AD Yandell DW p53 gene analysis of ovarian borderline tumors and stage I carcinomas Hum Pathol 1995, 26:387-92. 10.1016/0046-8177(95)90138-8 7705816
39. Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye S Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lindvall B Bacon M Birt A Andersen JE Zee B Paul J Baron B Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results J Natl Cancer Inst 2000, 92:699-708. 10.1093/ jnci/92.9.699 10793106
40. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial Lancet 2002, 360:505-515. 10.1016/S0140-6736(02)09738-6 12241653
41. Muggia FM Braly PS Brady MF Sutton G Niemann TH Lentz SL Alvarez RD Kucera PR Small JM Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study J Clin Oncol 2000, 18:106-115. 10623700
42. Zhao XD Zhang Y He SR Yang L Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma Ai Zheng 2005, 24:1542-1545. 16351810
43. Eisenhauer EL Tew WP Levine DA Lichtman SM Brown CL Aghajanian C Huh J Barakat RR Chi DS Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy Gynecol Oncol 2007, 106:381-7. 10.1016/j.ygyno.2007.04.012 17509673
44. Lichtman SM Wildiers H Chatelut E Steer C Budman D Morrison VA Tranchand B Shapira I AApro M International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients - an analysis of the medical literature J Clin Oncol 2007, 25:1832-43. 10.1200/JCO.2007.10.6583 17488981
45. Wasil T Lichtman SM Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly Oncologist 2005, 10:602-12. 10.1634/theoncologist.10-8-602 16177284
46. McGuire WP 3rd Current status of taxane and platinum-based chemotherapy in ovarian cancer J Clin Oncol 2003, 21:133-135. 10.1200/JCO.2003.01.066
47. Giannakakou P Sackett DL Kang YK Zhan Z Buters JT Fojo T Poruchynsky MS Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization J Biol Chem 1997, 272:17118-25. 10.1074/jbc.272.27.17118 9202030
48. Gonzalez-Garay ML Chang L Blade K Menick DR Cabral F A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance J Biol Chem 1999, 274:23875-82. 10.1074/jbc.274.34.23875 10446152
49. Mozzetti S Ferlini C Concolino P Filippetti F Raspaglio G Prislei S Gallo D Martinelli E Ranelletti FO Ferrandina G Scambia G Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients Clin Cancer Res 2005, 11:298-305. 15671559
50. Kavallaris M Kuo DY Burkhart CA Regl DL Norris MD Haber M Horwitz SB Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes J Clin Invest 1997, 100:1282-93. 508306 9276747 10.1172/JCI119642
51. Ferlini C Raspaglio G Mozzetti S Cicchillitti L Filippetti F Gallo D Fattorusso C Campiani G Scambia G The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance Cancer Res 2005, 65:2397-405. 10.1158/0008-5472.CAN-04-3065 15781655
52. Goncalves A Braguer D Kamath K Martello L Briand C Horwitz S Wilson L Jordan MA Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics Proc Natl Acad Sci USA 2001, 98:11737-42. 58799 11562465 10.1073/pnas.191388598
53. Carles G Braguer D Dumontet C Bourgarel V Goncalves A Sarrazin M Rognoni JB Briand C Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs Br J Cancer 1999, 80:1162-1168. 10.1038/sj.bjc.6690481 10376967
54. Xia L Wurmbach E Waxman S Jing Y Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis Leukemia 2006, 20:1009-1016. 10.1038/sj.leu.2404198 16572199
55. Shakuto S Fujita F Fujita M Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice Gan To Kagaku Ryoho 2006, 33:337-343. 16531714
56. Haldar S Basu A Croce CM Bcl-2 is the guardian of microtubule integrity Cancer Res 1997, 57:229-233. 9000560